Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data
Main Authors: | Granger, Benjamin, Combe, Bernard, Le Loet, Xavier, Saraux, Alain, Guillemin, Francis, Fautrel, Bruno |
---|---|
Format: | Online |
Language: | English |
Published: |
BMJ Publishing Group
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879338/ |
Similar Items
-
Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort
by: Fautrel, Bruno, et al.
Published: (2012) -
Evolution of Direct Costs in the First Years of Rheumatoid Arthritis: Impact of Early versus Late Biologic Initiation - An Economic Analysis Based on the ESPOIR Cohort
by: Chevreul, Karine, et al.
Published: (2014) -
Identifying patients with rheumatoid arthritis with moderate disease activity at risk of significant radiographic progression despite methotrexate treatment
by: Fautrel, B, et al.
Published: (2015) -
Validation of ACR/EULAR definition of remission in rheumatoid arthritis from RA practice: the ESPOIR cohort
by: Zhang, Bin, et al.
Published: (2012) -
Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR Cohort
by: Seror, Raphaèle, et al.
Published: (2016)